Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Taking the Stage: Scientific Conferences

Our scientists and clinicians are global experts in their field. The University of Kansas Cancer Center faculty present their work at dozens of scientific conferences each year.

Media inquiry? The cancer center communications team works with media to facilitate information requests and connect them with experts. Learn more.

Recent and Past Conferences

Abstracts listed below involve KU cancer center members and consortium partners Stowers Institute for Medical Research and Children’s Mercy.

  • Wednesday, December 9

    Special Poster Discussion 2
    8 am
    Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer

    Park KU, Gregory ME, Lustberg MB, Bazan JG, Shen c, Rosenberg SM, Blinder VS, Sharma P, Pusztai L, Partridge AH, Thompson A.

    Poster Session 2
    8 am
    PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial.  
    Paoletti C, Barlow WE, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma PGodwin AK, Thompson AM, Hayes DF, Rae J. 

    Poster Session 6
    8 am
    PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer.

    Yoder R, Kimler BF, Staley JM, Schwensen K, Wang YY, Finke K, O'Dea A, Nye L, Elia M, Crane G, McKittrick R, Pluenneke R, Madhusudhana S, Beck L, Rodriguez R, Shrestha A, Corum L, Marsico M, Godwin AK, Khan Q, Sharma P

    Poster Session 7
    8 am
    PS7-44: Energetics and LifestyLe In InheritEd Syndromes (ELLIE'S Study).  

    Nye LE, Cruz K, Friedman S, Rose D, Befort C, Sullivan DK, Hamilton-Reeves JM, Harlan-Williams LM, Behbod F, Wick J, Irwin M, Klemp J

    Poster Session 11
    8 am
    PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.  

    Aftimos P, Oliveira M, Punie K, Boni V, Hamilton E, Gucalp A, Shah P, Mina L, Sharma P, Bauman L, Campeau E, Attwell S, Snyder M, Norek K, Czibere A, Yu Y, Silverman MH, Lakhotia S, Domchek S, Litton J, Robson M. 

    Poster Session 13
    8 am
    PS13-16: Pharmacokinetic Evaluation of an Oral Paclitaxel DHP107 (Liporaxel®) in Patients with Recurrent or Metastatic Breast Cancer (MBC): Phase II study (OPERA, NCT03326102).

    Rugo HS, Pluard TJ, Sharma P, Melisko M, Al-Jazayrly G, Vidula N, Ji Y, Weng D, Lim H-S, Yoon KE, Cho HJ. 

    Thursday, December 10
    10 am
    GS3-05.  Classification of triple negative breast cancer (TNBC) by DNA Damage Immune Response (DDIR) signature and Homologous Recombination Deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial.
    Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes D, Sharma P

    10:15 am
    GS3-06.  Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

    Hurvitz SA, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamiltion E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortés J, Tsai M, Vahdat L, Diéras V, Carey L, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Bardia A. 

    Panel Discussion
    11:35 am - 12 pm    
    De-escalation trials: What makes sense, what is useless and what's crazy
    Moderator: Eric Winer 
    Panelists:Lisa Carey, Liz Garrett-Mayer, Tari A. King, Priyanka Sharma, Sara M. Tolaney, Julia R. White

    Spotlight Poster Discussion Session 5
    2:15 - 3:30 pm
    Mouse-intraductal (MIND): the first in vivo model to recapitulate the full spectrum of human dcis pathology. Behbod F, Hong Y, Limback D, Elsarraj HS, Harper H, Haines H, Hansford H, Ricci M, Kaufman C, Xu M, Zhang J, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Aripoli A, Huppe A, Winblad O, Balanoff C, Wagner J, Amin AL, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Futreal A, Thompson A, Hwang S, Fan F, On behalf of the Grand Challenge PRECISION consortium. 

    Friday, December 11
    10:15 am
    GS4-07. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore.

    van der Noordaa MEM, Yau C, Shad S, Osdoit M, Steenbruggen TG, de Croze D, Hamy A-S, Lae M, Reyal F, Del Monte-Millán M, Martin M, Lopez Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van 't Veer L, Symmans F, Esserman L. 

    Spotlight Poster Session 13
    1 pm – 2:15 pm
    Site of recurrence after neoadjuvant therapy: a multi-center pooled analysis.

    Shad S, van der Noordaa M, Osdoit M, de Croze D, Hamy A-S, Lae M, Reyal F, Martin M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Sonke G, Steenbruggen TG, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, Mackintosh L, Fang F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, Van't Veer L, Symmans F, Esserman L, Yau C. 

    Spotlight Poster Session 11
    2:15 pm – 3:30 pm
    Randomized trial of 12 months of omega-3 fatty acids vs placebo during a weight loss intervention in post-menopausal women at increased risk for breast cancer.

    Fabian CJ, Befort CA, Sullivan DK, Carlson SE, Nydegger JL, Kreutzjans AL, Powers KR, Phillips TA, Metheny T, Zalles CM, Giles ED, Hursting SD, Kimler BF

    Spotlight Poster Session 12
    3:30 pm - 4:30 pm
    Chronic Health Conditions and Quality of Life in Breast Cancer Survivorship

    Jennifer Klemp, PhD, MPH, MA, Chair,

  • 75: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

    Program: Oral Presentation
    Saturday, December 5, 2020: 7:30 AM

    Ryotaro Nakamura, M.D., Wael Saber, MD, MS, Michael J Martens, PhD, Alyssa Ramirez, Bart L. Scott, MD, Betul Oran, MD, MS, Eric Leifer, Ph.D., Roni Tamari, MD, Asmita Mishra, MD, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Peter Westervelt, MD, PhD, Sumithra Vasu, MD, MBBS, Mrinal M. Patnaik, MD, MBBS, Rammurti Kamble, MD, Stephen J. Forman, MD, Mikkael A. Sekeres, Frederick R. Appelbaum, MD, Adam M. Mendizabal, MS, Brent Logan, PhD, Mary M. Horowitz, MD, MS and Corey Cutler, MD, MPH, FRCPC

    24: A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results  
    Program: Oral Presentation
    Saturday, December 5, 2020: 7:30 AM

    Keith W. Pratz, MD, Mohamad Cherry, MD, MS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD, PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD, PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS and Ramon V. Tiu, MD

    135: High Doses of Targeted Radiation with Anti-CD45 Iodine Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Program: Oral Presentation
    Saturday, December 5, 2020: 9:30 AM

    Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD, MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD, PhD, Mitchell Sabloff, MSc, MD, FRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD PhD

    111: Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial
    Program: Oral Presentation
    Saturday, December 5, 2020: 9:30 AM

    Hartmut Döhner, Andrew H Wei, MBBS, PhD, Pau Montesinos, MD, PhD, Hervé Dombret, MD, Farhad Ravandi, MBBS, Hamid Sayar, MD, MSc, Kimmo Porkka, Irwindeep Sandhu, MD, Francesco Passamonti, Fabrizio Pane, MD, Tadeusz Robak, MD PhD, José F. Falantes, Andre C. Schuh, Gert Ossenkoppele, MD, PhD, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Gail J. Roboz, MD

    214: Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial
    Program: Oral Presentation
    Saturday, December 5, 2020: 12:15 PM

    Gail J. Roboz, MD, Hartmut Döhner, Christopher Pocock, MBBS, Hervé Dombret, MD, Farhad Ravandi, MBBS, Jun Ho Jang, MD, PhD, Dominik Selleslag, MD, Jiří Mayer, Uwe M. Martens, MD, Jane L. Liesveld, MD, Teresa Bernal del Castillo, MD, PhD, Ming-Chung Wang, MD, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, Julia Braverman, PhD, Salem Abi Nehme, PhD, C.L. Beach, PharmD and Andrew H Wei, MBBS, PhD

    301: Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era
    Program: Oral Presentation
    Saturday, December 5, 2020: 3:15 PM

    Dawn Maze, MD, FRCPC, MSc, Murat O. Arcasoy, MD, Ryan Henrie, MD, BSc, Sonia Cerquozzi, MD, Rammurti Kamble, MD, Samer Al Hadidi, MD, MSc, FACP, Abdulraheem Yacoub, MD, Mahmoud Elsawy, MB, Shireen Sirhan, MD, Anurag K. Singh, MD, Elliot Smith, BSc, Curtis Marcoux, MD MSc, Dietrich Werner, MD, FACP, FRCP, Wenda Greer, PhD, Auro Viswabandya, MD, Andrew Daly, MD, Hassan Sibai, MBBS, Caroline J McNamara, MBBS, Wei Xu, PhD, Katherine Lajkosz, Lynda Foltz, MD, FRCPC and Vikas Gupta, MD, FRCP, FRCPath

    1596: Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample
    Program: Poster Presentation
    Saturday, December 5, 2020

    Ghulam Rehman Mohyuddin, MD, Kellen Gil, Brian McClune, Nausheen Ahmed, Al-Ola Abdallah, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Leyla Shune, MD and Saqib Abbasi

    1582: Patterns and Growth of a Dedicated Pediatric Coagulation Consult Service in a Freestanding Children’s Hospital
    Program: Poster Presentation
    Saturday, December 5, 2020

    Shannon L Carpenter, MD, Eryn Bilynsky, BSN, RN, CCRC, Dena Wideman, MSN, ANP, Kristina D'Agostino, MSN, APRN, Lauren E Amos, MD, Mukta Sharma, MD, MPH and Michael Silvey, DO

    1091: Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A-r Infant Acute Lymphoblastic Leukemia Patients
    Program: Poster Presentation
    Saturday, December 5, 2020

    Sarah Mc Dermott, DO, Midhat S. Farooqi, MD, PhD, Azhar Saeed, MD, Byunggil Yoo, MS, Emily Farrow, PhD, CGC, Neil Miller, Patrick A. Brown, MD and Erin Guest, MD

    934: Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study
    Program: Poster Presentation
    Saturday, December 5, 2020

    Hillard Lazarus, Carolina Escobar, MD, Leland Metheny III, MD, Joseph P. McGuirk, DO, Tsila Zuckerman, MD, Mark Litzow, MD, Scott D. Rowley, MD, Racheli Ofir, PhD, Liran Shani, MD and Jacob M. Rowe, MB, BS

    1123: Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
    Program: Poster Presentation
    Saturday, December 5, 2020

    Morton Coleman, MD, FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD, PhD and Jeff P Sharman, MD

    1149: Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara
    Program: Poster Presentation
    Saturday, December 5, 2020

    Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD, PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD, PhD, Koji Kato, MD, PhD, Hideo Harigae, MD, PhD, Marie José Kersten, MD, PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD, PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz Offner, MD, PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD and Catherine Thieblemont, MD, PhD

    1154: Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2  
    Program: Poster Presentation
    Saturday, December 5, 2020

    Pierluigi Porcu, MD, Bradley Haverkos, MD, MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD, PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD, PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD, PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD and Douglas V. Faller, MD, PhD

    990: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients  
    Program: Poster Presentation
    Saturday, December 5, 2020

    Dries Deeren, MD, PhD, Johan A. Maertens, MD, PhD, Tara Lin, MD, Yves Beguin, MD, PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD5, Eytan Breman, Marie-Sophie Dheur, PhD, PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD and Frédéric F. Lehmann, MD

    036: CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial
    Program: Poster Presentation
    Saturday, December 5, 2020

    Andrew Wei, MBBS, PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD, PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Farhad Ravandi, MBBS

    1398: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
    Program: Poster Presentation
    Saturday, December 5, 2020

    Omar Nadeem, MD, Clifton C Mo, MD, Jacob P. Laubach, MD, Giada Bianchi, MD, Robert Redd, Peter Barth, Trevor J. Bayliss, MD, Vaishali Sanchorawala, MD, Leyla Shune, MD, Alexandra Distaso, Virginia Dalton, MS, APRN, Adam S Sperling, MD, PhD, Laura Amweg, Mary McKenney, NP, Kathleen Colson, BS, BSN, RN, Ella L Millard, Isabella Hou, Alexandra Savell, BS, Kelly Masone, BA, Nikhil C. Munshi, MD, Irene M. Ghobrial, MD, Kenneth Anderson, MD and Paul G. Richardson, MD

    1025: V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
    Program: Poster Presentation
    Saturday, December 5, 2020

    Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD, PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung and Vinod A. Pullarkat, MD

    354: Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants.
    Program: Oral Presentation
    Sunday, December 6, 2020: 9:45 AM

    Everett H Meyer, MD, PhD, Rasmus Hoeg, MD, Anna Moroz, MD, PhD, Bryan Xei, BS, Hsin-Hsu Wu, MD, Rahul Pawar, Kartoosh Heydari, MD, David B. Miklos, MD, PhD, Parveen Shiraz, MD, Lori S. Muffly, MD, MS, Sally Arai, MD, MS, Laura J. Johnston, MD, Robert Lowsky, MD, FRCP, Andrew R. Rezvani, MD, Judith A Shizuru, MD, PhD, Wen-Kai Weng, MD, PhD, Nathaniel Fernhoff, PhD, Gerhard Bauer, Arpita Gandhi, MD, MS, Amy Putnam, J. Scott Scott McClellan, MD, PhD, Bronwen E. Shaw, PhD, MRCP, FRCPath, Joseph P. McGuirk, DO, Mehrdad Abedi, MD and Robert S. Negrin, MD

    388: Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
    Program: Oral Presentation
    Sunday, December 6, 2020: 12:00 PM

    Sara Zarnegar-Lumley, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Zhuoxin Sun, PhD, Rhonda E. Ries, MA, Yi-Cheng Wang, MS, Amanda R. Leonti, MS, Matthew A. Kutny, MD, Derek Stirewalt, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Era L Pogosova-Agadjanyan, BS, Kristen Marie O'Dwyer, MD, Harry P. Erba, MD, PhD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD, Mark Litzow, MD, Ehab L. Atallah, MD, Selina M. Luger, MD, FRCPC, Ross L. Levine, MD, Todd M. Cooper, DO, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Soheil Meshinchi, MD, PhD and Katherine Tarlock, MD

    393: The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia
    Program: Oral Presentation
    Sunday, December 6, 2020: 1:15 PM

    Jenny L. Smith, MSc, MEd, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Fabiana Ostronoff, MD, Gertjan J.L. Kaspers, Prof. MD, PhD, Henrik Hasle, PhD, Christian M. Zwaan, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd M. Cooper, DO, Richard Aplenc, MD, PhD, Alan S. Gamis, MD, MPH, Edward A. Kolb, MD, Bianca F. Goemans, MD, PhD and Soheil Meshinchi, MD, PhD

    479: Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
    Program: Oral Presentation
    Sunday, December 6, 2020: 2:00 PM

    John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, Md, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Alessandro M. Vannucchi, MD and Abdulraheem Yacoub, MD

    482: PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients.  
    Program: Oral Presentation
    Sunday, December 6, 2020: 2:45 PM

    Marina Kremyanskaya, Yelena Ginzburg, MD, Andrew T. Kuykendall, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel K Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD, Srdan Verstovsek, MD, PhD and Ronald Hoffman, MD

    468: Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
    Program: Oral Presentation
    Sunday, December 6, 2020: 3:00 PM

    Liora M. Schultz, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L Phillips, MD, Jenna Rossoff, MD, Heather Stefanski, MD, PhD, Julie-An Talano, MD, Amy Moskop, MD, Steven P. Margossian, MD, PhD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy Keating, MD, Rachel Wilcox, Cara A Rabik, MD, PhD, Vanessa Fabrizio, MD, Michael Kunicki, Vasant Chinnabhandar, MD, A. Yasemin Goksenin, MD, PhD, MA, MPH, Kevin J. Curran, MD, Crystal L. Mackall, MD and Theodore W. Laetsch, MD

    2039: Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era
    Program: Poster Presentation
    Sunday, December 6, 2020

    Aung M Tun, MD, Raphael Mwangi, Brian K. Link, MD, Andrew L. Feldman, MD, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Anne J. Novak, PhD, Jose C Villasboas, MD, Umar Farooq, MD, Sergei Syrbu, MD, PhD, James R. Cerhan, MD, PhD and Thomas M. Habermann, MD

    1936: Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release
    Program: Poster Presentation
    Sunday, December 6, 2020

    Jenna Rossoff, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L Phillips, MD, Heather Stefanski, MD, PhD, Julie-An Talano, MD, Amy Moskop, MD, Steven P. Margossian, MD, PhD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy Keating, MD, Rachel Wilcox, Cara A Rabik, MD, PhD, Vanessa Fabrizio, MD, Michael Kunicki, Vasant Chinnabhandar, MD, A. Yasemin Goksenin, MD, PhD, MA, MPH, Kevin J. Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD and Liora M. Schultz, MD

    2557: A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma.  
    Program: Poster Presentation
    Sunday, December 6, 2020

    Ghulam Rehman Mohyuddin, Jill Hampton, Muhammad Aziz, Sadik Khuder, Ph.D, Saad Ullah Malik, MD, Brian McClune and Al-Ola Abdallah, MD

    3260: First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated Γδ T Cells Following Haploidentical Bone Marrow 
    Program: Poster Presentation
    Sunday, December 6, 2020

    Lawrence S. Lamb Jr., PhD, Melissa Jo Beelen, Samantha Langford Youngblood, BS, Rupal Soder, PhD, Sunil Abhyankar, MD and Joseph P. McGuirk, DO

    2285: Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data  
    Program: Poster Presentation
    Sunday, December 6, 2020

    Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD, PhD, Erica Kim and Brian G.M. Durie, MD

    2314: Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
    Program: Poster Presentation
    Sunday, December 6, 2020

    David S. Siegel, MD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD, PhD, FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, FRCPC, Christopher S. Seet, MD, PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD, PhD and Nizar Bahlis, MD

    1946: Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
    Program: Poster Presentation
    Sunday, December 6, 2020

    Jorge E. Cortes, MD, Tara Lin, MD, Geoffrey L Uy, MD, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet, MD

    1917: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial
    Program: Poster Presentation
    Sunday, December 6, 2020

    Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD, PhD, Hamid Sayar, MD, MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD8, William Tse, MD, FACP, Sang Kyun Sohn, MD, PhD, Devendra Hiwase, MBBS, MD, FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Hervé Dombret, MD

    1853: Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies
    Program: Poster Presentation
    Sunday, December 6, 2020

    Nan of Wang, PhD, Corinne Marie Lavasseur, BA, Hongxia Yan, MS, Scott Younger, PhD, Bertil Glader, MD, PhD, Kathleen M. Sakamoto, MD, PhD, Lionel Blanc, PhD and Anupama Narla, MD

    621: CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial
    Program: Oral Presentation
    Monday, December 7, 2020: 9:15 AM

    Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP and Thorsten Braun, MD, PhD

    635: Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders
    Program: Oral Presentation
    Monday, December 7, 2020: 12:15 PM

    Jeffrey E. Lancet, MD, Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Donna E. Hogge, Scott R. Solomon, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD, PhD, Daniel H. Ryan, Stefan Faderl, Yu-Lin Chang and Jorge E. Cortes, MD


    636: Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
    Program: Oral Presentation
    Monday, December 7, 2020: 12:30 PM

    Eytan M. Stein, MD, Ying Huang, MS, MA, Uma Borate, Maria R. Baer, M.D., Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark Litzow, MD, Tara Lin, MD, Prapti Patel, MD, Matthew C Foster, MD, Michael Boyiadzis, MD, Robert H. Collins, MD, Jo-Anne Vergilio, M.D., Nyla A Heerema, PhD, Leonard Rosenberg, Ashley Owen Yocum, PhD, Timothy Chen, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Abigail Shoben, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Alice S. Mims, MD

    692: CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial 
    Program: Oral Presentation
    Monday, December 7, 2020: 2:30 PM

    Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD and Gert Ossenkoppele, MD, PhD

    747: Economic and Clinical Burden of Virus Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation 
    Session Name: Health Services Research—Malignant Conditions (Lymphoid Disease) I

    Program: Oral Presentation
    Monday, December 7, 2020: 2:45 PM

    Presenter: Joseph P. McGuirk, DO, The University of Kansas Cancer Center 

    3267: A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC Derived TCR Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell
    Program: Poster Presentation
    Monday, December 7, 2020

    Jae H. Park, MD, Nitin Jain, MD, Andy Chen, MD, PhD, Joseph P. McGuirk, DO, Monica Diaz, Bahram Valamehr, PhD, Yu-Waye Chu, MD and Januario E. Castro, MD

    2887: CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells
    Program: Poster Presentation
    Monday, December 7, 2020

    Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta and Daniel Lopes de Menezes, PhD

    3346: Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML
    Program: Poster Presentation
    Monday, December 7, 2020

    Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD, PhD, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet, MD


  • 4703 / 6 - Role of REST in the regulation of MMP24 and estrogen sensitivity in breast cancer

    Aditya M. VargheeseAshley CloudSumedha GunewardenaRaeann ShimakEaswari KumaraswamyRoy A. JensenVargheese M. Chennathukuzhi.

    6405 / 29 - Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting Notch signaling

    Scott James WeirPrasad DandawatePrabhu RamamoorthyParthasarathy RanjarajanRobyn WoodAmanda BrinkerBenjamin Woolbright, Mehmet TanolTammy HamWilliam McCullochMichael DaltonMichael J. BaltezorRoy A. JensenJohn A. Taylor IIIShrikant Anant.

    5150 / 5 - MIF-2 in bladder cancer: potential therapeutic target

    Ganeshkumar RajendranBenjamin L. WoolbrightErika AbbottAustin MartinKatie DennisJohn Arthur Taylor III.

    1120 / 2 - Randomized clinical trial of a flaxseed lignan in pre-menopausal women at high risk for development of breast cancer

    Carol J. FabianSeema A. KhanJudy E. GarberWilliam C. DooleyLisa D. YeeCarola M. ZallesTrina MethenyTeresa A. PhillipsJinxiang HuBrian K. PetroffStephen D. HurstingBruce F. Kimler.

    1379 / 15 - Entinostat induces PARPi sensitivity across multiple ovarian cancer models

    Vijayalaxmi G. GuptaShariska Petersen, Jeff HirstKatherine RobyHarsh Pathak, Meghan KuschAndrew WilsonAndrew GodwinDineo Khabele.

    6176 / 16 - Preclinical analysis: BCN057 induces apoptosis in Kras mutant tumors

    Andrew J. NorrisPayel Bhanja, Felipe Rodriguez TiradoAndrew HooverElizabeth M. SingerWilliam McBrideSubhrajit Saha.

    4140 / 17 - Dissecting the structural basis for rational inhibitor design: Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1

    Lan LanMinli XingMaithri KashipathyJustin Douglas, Philip GaoKevin BattaileRobert HanzlikScott LovellLiang Xu.

    2662 / 10 - Mitochondrial genetics appear to alter immune cell development/trafficking

    Thomas C. BeadnellAmanda E. BrinkerCori FainCarolyn J. VivianDanny R. Welch.

    2026 / 4 - Outcomes in elderly patients with non-small-cell lung cancer receiving immune checkpoint inhibitor therapy: A real world experience

    Jacob RippGhulam R. MohyuddinMohammed Al-JumayliChao Huang.

    5417 / 19 - Genomic analysis of infant KMT2A-r acute lymphoblastic leukemia reveals weak association with underlying germline cancer predisposition

    Azhar Saeed, Midhat FarooqiByunggil YooRumen KostadinovEmily FarrowNeil MillerPatrick BrownErin Guest.

    1205 / 13 - Leveraging genome-wide methylation data to understand lung cancer risk in heavy smokers

    Laurie GrieshoberJincheng ShenStefan GrawMatt J. BarnettMark D. ThornquistGary E. GoodmanChu ChenDevin C. KoestlerCarmen J. MarsitJennifer A. Doherty.

    6474 / 8 - FAT1 and CASP8 co-mutations are associated with poor prognosis in HPV negative head and neck squamous cell carcinoma

    Emrullah YilmazDavid LeeAndrew CowanGregory GanMichelle OzbunYan Guo.

    784 / 21 - Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

    Alexander E. PerlJorge E. CortesSiddhartha Ganguly, Samer K. KhaledAlwin KrämerGiovanni MartinelliNigel H. RussellKen C. N. ChangKazunobu KatoYuhu YanLi-An XuSergey KorkhovTobias GünnelHiroyuki SumiArnaud LesegretainFlora BerishaDerek MiresAziz BenzohraTakeshi IsoyamaCedric Dos SantosMark J. Levis.

    CT162 - The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

    Ulrich JaegerNina WorelJoseph P. McGuirk, Peter A. RiedellIsabelle FleuryPeter BorchmannSimon NewsomeAhmed M. AbdelhadyAlessandra ForcinaLida Bubuteishvili PacaudEdmund K. Waller.

    LB-258 / 2 - Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

    Barbara BurtnessDanny RischinRichard GreilDenis SoulièresMakoto TaharaGilberto De CastroAmanda PsyrriNeus BastéPrakash NeupaneÅse BratlandThorsten FuerederBrett G. M. HughesRicard MesiaNuttapong NgamphaiboonTamara RordorfWan Zamaniah Wan IshakJoy GeRamona SwabyBurak GumuscuKevin Harrington.

    1921 / 5 - TheDDB2 intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-AAML0531 trial

    Vivek M. ShastriLata ChauhanTodd A. AlonzoYi-Cheng WangRichard AplencBetsy A. HirschAlan S. Gamis, Soheil MeshinchiJatinder K. Lamba.

    3417 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort

    Young Kwang ChaeMegan OthusSandip Pravin PatelMark ZalupskiAnup KasiMaged KhalilAparna KalyanBlase PoliteSarah FentonSewan GurungChristine M. McLeodFrancis GilesHelen X. ChenElad SharonEdward MayersonMelissa PletsChristopher W. RyanCharles D. BlankeRazelle Kurzrock.

State of the Cancer Center Presentation

"State of the Cancer Center" presentation by Dr. Roy Jensen, director of The University of Kansas Cancer Center from KU Cancer Center's Cancer Research Week 2020 event.

Highlights

Hear from our faculty as they discuss major findings presented at ASCO 2020. 

 

ASCO Quality Care Symposium

Dr. Lauren Nye’s presentation from the 2020 ASCO Quality Care Symposium

News

Related links